Objectives: The general objective of this study is to test the hypothesis that administration of convalescent plasma from donors with previous diagnosis of severe COVID-19 pneumonia is safe and associated with a decrease in all-cause in-hospital mortality among hospitalized patients with COVID-19 at 30 days in comparison with standard treatment alone. The secondary objectives are: 1) to assess the efficacy of convalescent plasma to reduce the length of hospitalization;2) to assess the efficacy of convalescent plasma to reduce the length of ICU stay;and 3) to assess the efficacy of convalescent plasma on reducing the requirement of invasive mechanical ventilation or ICU stay. Trial design PERUCONPLASMA is a IIb phase open label, randomised, superiority clinical trial with 1:1 allocation taking place in real life routine clinical practice at public hospitals in Lima, Peru. Participants will be randomised to receive convalescent plasma along with local standard treatment or local standard treatment alone. After allocation all participants will be followed for a total of 30 days or until hospital discharge, whichever occurs first.
Randomised Clinical Trial to Evaluate Safety and Efficacy of Convalescent Plasma Use Among Hospitalized Patients with COVID-19 (PERUCONPLASMA): A Structured Summary af a Study Protocol for a Randomised Controlled Trial